

COMPANY FACT SHEET



Antigenics is an emerging biopharmaceutical company developing treatments for cancers and infectious diseases. The company's product portfolio includes its late-stage development candidate Oncophage® (vitespen), a patient-specific therapeutic cancer vaccine that has recently been

approved in Russia for use as an adjuvant treatment for renal cell carcinoma (RCC) in patients at intermediate risk of disease recurrence¹; and the QS-21 Stimulon® Adjuvant, a vaccine adjuvant being evaluated by Antigenics' corporate licensees in several Phase 2 and 3 clinical trials.

LEADERSHIP

Executive Management

Garo H. Armen, PhD
Chairman and Chief Executive Officer

John Cerio
Vice President, Human Resources

Stephen Monks, PhD
Vice President, Manufacturing and PAT

Shalini Sharp
Chief Financial Officer and Vice President

Sunny Uberoi
Vice President, Corporate Communications

Karen Higgins Valentine
Vice President & General Counsel

Kerry A. Wentworth
Vice President, Regulatory Affairs and Clinical Operations

Directors

Garo H. Armen, PhD
Chairman and Chief Executive Officer

Brian Corvese
Vencor Capital

Tom Dechaene

John N. Hatsopoulos
American DG Energy

Wadih Jordan
NearEast Pharma

Hyam I. Levitsky, MD
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Tim Rothwell

Timothy R. Wright
Covidien

CORPORATE HIGHLIGHTS

IN 2008, ONCOPHAGE APPROVED IN RUSSIA AND COMMERCIAL LAUNCH EFFORTS ONGOING FOR INTERMEDIATE RISK RCC

IN 2008, A MARKETING AUTHORIZATION APPLICATION WAS SUBMITTED TO THE EUROPEAN MEDICINES AGENCY REQUESTING APPROVAL FOR ONCOPHAGE IN EARLIER-STAGE, LOCALIZED RENAL CELL CARCINOMA UNDER THE CONDITIONAL AUTHORIZATION PROVISION

A PHASE 1/2, INVESTIGATOR-SPONSORED TRIAL EVALUATING ONCOPHAGE IN GLIOMA IS ONGOING AT UCSF; DATA SHOW IMMUNE RESPONSE IN ALL TREATED PHASE 1 PATIENTS

QS-21 STIMULON® ADJUVANT BEING EVALUATED BY ANTIGENICS' CORPORATE LICENSEES IN APPROXIMATELY 16 CLINICAL-STAGE VACCINES, INCLUDING TWO IN PHASE 3 CLINICAL TRIALS

TECHNOLOGIES PROTECTED BY MORE THAN 60 ISSUED US PATENTS

Members of the Medical Advisory Council

Michael Atkins, MD
Beth Israel Deaconess Medical Center

Ronald M. Bukowski, MD
Cleveland Clinic


Larry W. Kwak, MD, PhD
M.D. Anderson Cancer Center

Hyam I. Levitsky, MD
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Giorgio Parmiani, MD
Istituto Nazionale per lo Studio e la Cura dei Tumori

Andrew T. Parsa, MD, PhD
University of California, San Francisco

David R. Spriggs, MD
Memorial Sloan-Kettering Cancer Center



NASDAQ: AGEN

SHARES OUTSTANDING
78.2 MILLION (6/15/09)

MARKET CAPITALIZATION
\$161 MILLION (6/15/09)

INVESTOR RELATIONS
SHALINI SHARP
TEL: 800.962.AGEN (2436)
E-MAIL: IR@ANTIGENICS.COM

CORPORATE COMMUNICATIONS
SUNNY UBEROI
TEL: 212.994.8206
E-MAIL: SUBEROI@ANTIGENICS.COM

ANTIGENICS INC.
3 FORBES ROAD
LEXINGTON, MA 02421
TEL: 781.674.4400
FAX: 781.674.4200

ANTIGENICS.COM

PRODUCT HIGHLIGHTS

Oncophage® (vitespen)

Oncophage (vitespen) is Antigenics' investigational patient-specific therapeutic cancer vaccine based on gp96, a heat shock protein (HSP). Oncophage is designed to contain the 'antigenic fingerprint' of the individual patient's specific cancer and to stimulate the immune system to recognize unique antigens present on each patient's cancer cells. Potentially applicable to all cancer types, Oncophage has been studied in nearly 800 patients in eight cancer indications to date, and was well tolerated in these studies.

Data from Antigenics' Phase 3 trial of Oncophage in non metastatic RCC showed a 48 percent decreased risk of recurrence in intermediate risk patients (AJCC Stage Ib/II high-grade, III T1/2/3a low-grade). While median recurrence-free survival (RFS) has not yet been reached, results from the 25th percentile indicate that RFS was extended by approximately 1.7 years in the Oncophage arm. In a Phase 3 study of Oncophage in metastatic melanoma, overall median survival time in a subgroup of patients who received at least 10 injections of the vaccine, increased by 29 percent compared with those in the physician's choice arm (16.5 months versus 12.8 months, respectively). Further evaluation of this same patient group by AJCC stage, reveals that for patients with stage m1a and m1b disease, overall median survival time was increased by 143 percent in the Oncophage arm compared with those in the physician's choice arm (31.2 versus 12.8 months).

An investigator-sponsored Phase 1/2 study, being conducted at the Brain Tumor Research Center at the University of California, San Francisco, evaluating Oncophage as a treatment for recurrent glioma, showed tumor-specific immune response in all treated Phase 1 patients, the Phase 2 portion is currently ongoing. Antigenics is evaluating opportunities to investigate Oncophage in combination with other treatments.

Oncophage has recently been approved for commercial use in Russia as an adjuvant treatment for renal cell carcinoma (RCC), the most common type of kidney cancer, in patients at intermediate risk of disease recurrence.¹ The European Medicines Agency is currently reviewing a marketing application for Oncophage in patients with earlier-stage RCC and a decision is expected in 2010.

QS-21 Stimulon® Adjuvant

One of the most widely tested vaccine adjuvants under development, Antigenics' QS-21 has been licensed by industry leaders such as GlaxoSmithKline, Elan and Sanofi-Aventis for use in a variety of vaccines. QS-21 is currently being evaluated by Antigenics' partners in approximately 16 clinical vaccines in a number of indications including cancer and infectious disease.

The first vaccine containing QS-21 could reach the market and provide revenues to Antigenics by 2012.

PRODUCT PIPELINE

CANCER

Oncophage®

Renal cell carcinoma (nonmetastatic)[§]

Melanoma

Renal cell carcinoma (metastatic)

Colorectal cancer

Non-small cell lung cancer

Glioma*†

Gastric cancer


Pancreatic cancer

PARTNERED PROGRAMS

QS-21 Stimulon®

Adjuvant

More than 20 indications



[§]Approved only in Russia for the treatment of intermediate-risk RCC; under review with EMEA

*Currently enrolling

†Investigator-sponsored

¹Intermediate-risk RCC is defined as primary tumor stage T1 or T2 high grade or pT3a low grade; no nodal involvement or no known residual or metastatic disease after surgical resection of localized RCC tumor.